Skip to main content

LONG ACTING ART: WHAT YOU NEED TO KNOW

Long-Acting ART: What You Need to Know

This month, pharmacist Gary Meyers discussed intramuscular cabotegravir-rilpivirine (CAB-RPV) as the first approved long-acting antiretroviral treatment regimen. He discussed who is eligible and why long-acting therapy may help patients. He also explained why usage has been limited thus far due to clinical factors, insurance coverage, and logistical barriers.

Objectives:

By the end of this presentation, attendees were able to:

  • Understand more about long-acting antiretroviral therapy;
  • Know who is eligible for long-acting therapy;
  • What will be different for patients switching to long-acting ARV;
  • Know dosing recommendations and appropriate schedules for long-acting antiretroviral therapy; and,
  • Understand the appropriate steps if a patient misses a dose.

Contact Darci Bultje for the recording.

WEBINAR: JULY 26, 2023

Check out our Clearinghouse Resources.